Business
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. marketsJoenja® revenue was US$14.1 million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentumReaffirmed 2026 total revenue guidance of US$405 - US$425 million (8% - 13% g
About this update from Pharming Group Nv
[{"type":"image","alt":"Pharming Group N.V.","displaySize":"","headline":null,"caption":"Pharming Group N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J5Zq9ohH.Typ7TvSuah8Jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/J5Zq9ohH.Typ7TvSuah8Jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Joenja® revenue was US$14.1 million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Reaffirmed 2026 total revenue guidance of US$405 - US$425 million (8% - 13% growth)","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated positive net cash flow from operations of US$2.0 million in the quarter","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Joenja® approved in Japan and received positive CHMP opinion for APDS","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Resubmitted pediatric sNDA to the FDA for Joenja® (leniolisib) for highest doses; plan additional sNDA this summer for lowest doses","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharming to host a conference call today at 13:30 CEST (7:30 am EDT)","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":880,"olType":false},{"type":"text","content":"Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR)...